TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A University of Michigan-led study found that experimental compound DT-109 improved metabolic dysfunction-associated steatohepatitis (MASH) in mice and nonhuman primates. The researchers say it reduced ammonia-producing gut bacteria and helped restore the intestinal barrier; the findings are preclinical and do not establish safety or effectiveness in people.
Researchers at the University of Michigan report that experimental compound DT-109 improved MASH, a severe form of fatty liver disease, in mice and nonhuman primates by targeting processes in the gut. The study, published in The Journal of Clinical Investigation, offers a possible treatment strategy, but it does not show that the drug works or is safe in humans.
The team found that DT-109 reduced levels of Clostridium perfringens, a gut bacterium that produces ammonia, and lowered ammonia in the intestines of both animal groups. The researchers say excess ammonia can damage the gut’s protective lining. When that barrier is weakened, microbial products may enter the bloodstream and reach the liver, where they can contribute to inflammation.
In the study, strengthening the intestinal barrier limited the movement of potentially harmful substances beyond the gut. The researchers also reported reduced liver inflammation and less severe MASH in nonhuman primates. The report describes this as a mechanism connecting changes in gut microbes with liver protection; the animal results do not establish that the same effects will occur in patients.
DT-109 is a glycine-based tripeptide, a small molecule made of three amino acids. The team had previously reported benefits in animal studies, but the new work investigates how the compound may produce them. The study’s central finding is that its effects appear to begin in the gastrointestinal tract and extend through the gut-liver relationship, rather than targeting only the liver itself.
A Gut-Based Route to Liver Protection
MASH can involve liver fat accumulation, inflammation and cell damage. Over time, it may progress to cirrhosis, liver cancer or liver failure. The source report estimates that the disease affects about 7% of the world’s population, while also noting that effective treatment options remain limited.
The findings matter because they point to a potential way to interrupt a chain of processes associated with liver injury: ammonia-producing bacteria, damage to the intestinal lining, and the movement of microbial products toward the liver. If later research supports this mechanism in people, treatment could potentially address contributors to inflammation outside the liver itself. At this stage, that is a research possibility, not an established clinical benefit.
The study also reported effects in nonhuman primates, whose liver biology and gut microbial communities are described as more similar to humans’ than those of mice. That makes the results relevant to further investigation, but it does not substitute for human trials or establish a dose, safety profile or clinical outcome.
gut health supplements for liver support
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What Earlier DT-109 Studies Found
The research builds on earlier animal work by the same team that found DT-109 could improve MASH, according to the source report. The newer study focuses on explaining those effects, examining gut bacteria, ammonia, intestinal barrier function and liver inflammation together.
The proposed mechanism involves the gut-liver axis: substances absorbed from the intestines can travel to the liver through the bloodstream. The researchers say that microbial products crossing a compromised intestinal barrier may contribute to liver inflammation and immune activity, including excessive activation of CD8+ T cells. The study links those processes in animal models; it does not establish their relative importance in human MASH.
The source also refers to prior nonhuman-primate research in which DT-109 reduced atherosclerotic plaque formation and prevented vascular calcification. Those findings are separate from the MASH results and do not establish DT-109 as a treatment for cardiovascular disease.
“We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression.”
— Eugene Chen, senior author and professor of cardiovascular medicine at the University of Michigan Medical School
Human Benefits Remain Unproven
The reported evidence comes from mice and nonhuman primates. The source material does not report human trials, clinical outcomes, or evidence that DT-109 can reverse MASH in people. It also does not provide details on a human dose, potential side effects, long-term safety, or when clinical testing might begin.
The animal findings support the researchers’ proposed gut-based mechanism, but the extent to which it applies to human disease remains unknown. The report does not provide study sample sizes, treatment duration, or enough information here to assess how large or lasting the effects were. It is also unclear whether DT-109 would benefit people at different stages of MASH or those with advanced liver damage.
Accordingly, descriptions of the compound as a potential treatment should be understood as research prospects, not medical advice or evidence that patients can access an effective therapy. The findings do not justify changing prescribed care.
Further Testing Must Establish Safety
The next evidence needed is whether DT-109 can be tested safely and effectively in people. The source report does not announce a clinical trial timetable or say that human testing has begun, so the immediate path and timing remain unclear.
Future research would need to assess safety, dosing and whether changes in gut bacteria and barrier function translate into meaningful liver outcomes for patients. Researchers would also need to establish how any effect varies by disease severity and how long it lasts. Until such evidence is available, DT-109 remains an experimental compound studied in animals, not a proven treatment for MASH.
Key Questions
What is DT-109?
DT-109 is an experimental glycine-based tripeptide studied for its effects on MASH in animals. The report describes it as acting primarily in the gastrointestinal tract.
Did DT-109 reverse fatty liver disease in people?
No human results are reported. The study found improvements in mice and nonhuman primates; whether the compound helps people is unknown.
How might the compound affect the liver?
Researchers say DT-109 reduced ammonia-producing Clostridium perfringens and helped protect the intestinal lining. That may limit the movement of microbial products toward the liver, where they can contribute to inflammation.
When could DT-109 become available?
The source report gives no clinical-trial schedule or approval timeline. The compound remains experimental, and human safety and effectiveness have not been established.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
